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ABSTRACT 
 
Background: The need to review cervical cancer prevention strategies has been triggered by the 
availability of new prevention tools linked to human papillomavirus (HPV): vaccines and 
screening tests. To consider these innovations, information on HPV type distribution and natural 
history is necessary. This is a five-year follow-up study of gynecological high-risk (HR) HPV 
infection among a Chilean population-based cohort of women. 
 
Findings: A population-based random sample of 969 women from Santiago, Chile aged 17 years 
or older was enrolled in 2001 and revisited in 2006. At both visits they answered a survey on 
demographics and sexual history and provided a cervical sample for HPV DNA detection 
(GP5+/6+ primer-mediated PCR and Reverse line blot genotyping). Follow-up was completed by 
576 (59.4%) women; 45 (4.6%) refused participation; most losses to follow-up were women who 
were unreachable, no longer eligible or had missing samples. HR-HPV prevalence increased by 
43%. Incidence was highest in women <20 years of age (19.4%) and lowest in women >70 (0%); 
it was three times higher among women HR-HPV positive versus HPV negative at baseline 
(25.5% and 8.3%; OR 3.8, 95% CI 1.8-8.0). Type-specific persistence was 35.3%; it increased 
with age, from 0% in women <30 years of age to 100% in women >70. An enrollment Pap result 
ASCUS or worse was the only risk factor for being HR-HPV positive at both visits.  
 
Conclusions: HR-HPV prevalence increased in the study population. All HR-HPV infections in 
women <30 years old cleared, supporting the current recommendation of HR-HPV screening for 
women >30 years.  
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FINDINGS 
 
Background 
Most research on the natural history of human papillomavirus (HPV) infection and its progression 
towards cancer has been conducted in developed areas. In Chile, a middle developing country, the 
only two population-based studies to date analyzed the prevalence of HPV at one point in time 
[1,2]. Chile has a well-organized nationwide cervical cancer prevention program based on 
Papanicolaou screening, which, after an initial impact on cervical cancer mortality, has not 
produced a significant decrease in the last decade [3]. Moreover, Chile currently has a high 
socioeconomic status differential in cervical cancer mortality (C. Ferreccio, unpublished 
observations). The need to review prevention programs has been triggered by the availability of 
two new effective prevention tools linked to HPV: vaccines and screening tests. To consider these 
innovations, countries should have baseline information on HPV type distribution in their 
populations, as well as knowledge of how these infections evolve. 
 
Methods 
In 2001 we studied the prevalence of gynecological HPV among a population-based sample of 
969 women 17 years of age and older, from a low socio-economic urban area of Santiago. Results 
and detailed description of enrollment and data collection procedures were previously reported 
[1]. Five years later we re-examined these women with the objectives of measuring high-risk (HR) 
HPV prevalence at this second point in time, and assessing rates and risk factors of HR-HPV 
persistence.  We attempted to contact these women for follow-up by home visits: 182 were not 
reachable, 45 declined participation, 22 were no longer eligible (pregnancy, hysterectomy, recent 
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surgery, death) and 144 were excluded due to missing cervical samples. Therefore, data for the 
present analysis was available for 576 women (59.4%). At enrollment and follow-up, participants 
signed an informed consent form and completed a questionnaire on demographic and behavioral 
characteristics.  
 
Participants attended a health center where a midwife collected cervical samples for HPV testing. 
An Ayre spatula was used to obtain exfoliated cervical cells and then placed in a tube with PBS; 
additionally, a spatula and cytobrush used for a Pap smear obtained at the same visit were washed 
in this tube. In both 2001 and 2006, HPV DNA testing was performed at the Department of 
Pathology of the VU University Medical Center in Amsterdam, the Netherlands. Specimens were 
tested for the presence of HPV DNA using a GP5+/6+ primer-mediated PCR and enzyme immune 
assay. Reverse line blot genotyping was used to type for 44 HPV genotypes, 14 HR-HPV (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) [4]. 
 
Multivariate comparison of participants and non-participants in the follow-up examination was 
performed using logistic regression to identify predictors of participation. Prevalence of HR-HPV 
infection in 2001 and 2006 was compared, using prevalence rate ratios. Risk factors for HR-HPV 
incidence and persistence (age, marital status, schooling, number of children, age of first sexual 
intercourse, lifetime number of sexual partners, high-risk sexual partner, condom use, history of 
sexually transmitted disease, hormonal contraception, smoking, history of previous Pap tests, and 
an abnormal baseline Pap test) were examined with univariate analysis; variables significant at P 
value < 0.2 were then entered in multivariate models. Sexual behavioral changes in the study 
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period were explored as risk factors for HR-HPV incidence. Statistical analyses were performed 
using SPSS version 17 for Windows.  
 
Results 
Sociodemographic characteristics of the study sample are presented in Table 1. Because it was not 
initially designed as a prospective study, we could only recontact 59% of the original cohort; 
losses to follow-up were mainly due to changes in address (182) or loss of cervical samples (144). 
Among participants in the follow-up study, lower schooling and never using a condom were 
significantly higher in multivariate analysis (OR 1.94, 95% CI 1.2-3.2 and OR 2.00, 95% CI 1.0-
3.9 respectively).  
 
The HR-HPV infections identified in the participants at baseline and follow-up are presented in 
Table 2. HR-HPV infection increased by 43%, from 8.8% to 12.7%. HPV16 prevalence did not 
change markedly in the period (2.1% - 3.3%); the largest increase of a particular HR-HPV 
genotype was for HPV18 (0.5% to 2.8%), which became the second most common HR-HPV in 
2006 (fifth in 2001).  
 
Prevalence, incidence and persistence of HR-HPV infections according to baseline age groups are 
presented in Table 3. In both years, HPV prevalence followed a U-curve, being highest at ages 
under 20 years (13.9% - 19.4%) and over 70 years (16.7% - 16.7%). Incidence was highest in 
women under 20 years old (19.4%) and lowest in women over 70 years old (0%). Incidence of 
new HR-HPV among women HR-HPV positive at baseline was three times higher (25.5%) than 
among women HPV negative at baseline (8.3%) (OR 3.8, 95% CI 1.8-8.0). In univariate analysis, 
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baseline characteristics significantly associated with acquiring new HR-HPV types (n=59), using 
women who did not acquire a HR-HPV (n=517) as referent, were being younger than 30 years and 
not having a previous Pap test (Table 1); only the latter remained significant in multivariate 
analysis (OR 0.36, 95% CI 0.15-0.88).  Some behavioral changes in the study period were 
associated with acquiring a new HR-HPV, however they did not reach statistical significance: 
becoming single or separated (OR 1.61, 95% CI 0.75-3.45), having new sexual partners (OR 1.12, 
95% CI 0.46-2.74), having a new high-risk sexual partner (OR 1.38, 95% CI 0.50-3.77) and 
beginning smoking (OR 1.63, 95% CI 0.54-4.89). 
 
Of the 576 participants, 27 (4.7%) tested positive for any HR-HPV (regardless of type) both years 
and 427 (74.1%) were HPV negative both years. In univariate analysis, baseline characteristics 
associated with non-type-specific HR-HPV persistence, using women who remained HR-HPV 
negative as referent, were low schooling (OR 2.76, 95% CI 1.02-7.43) and an abnormal baseline 
Pap test (OR 12.55, 95% CI 3.30-47.71); however, only the later remained significant in 
multivariate analysis (OR 10.73, 95% CI 2.75-41.95). 
 
HR-HPV type-specific persistence was 35.3%. All type-specific persistence occurred in women 
older than 30 years of age, increasing from 33.3% in women 31-40 years old to 100% in women 
over 70 years old. Additionally, a significant association with type-specific HR-HPV persistence 
(n=18), in comparison with women who cleared a HR-HPV infection (n=33), was observed with 
low schooling (Table 1); however, this did not reach statistical significance in multivariate 
analysis. We did not identify significant differences in persistence rates among different HR-HPV 
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types: 5 out of 15 (33.3%) HPV 16/18 infections persisted, compared with 13 out of 44 (29.5%) 
other HR-HPV infections. 
 
Discussion 
Reasons for the increase in HR-HPV infection are unclear, especially since the increase in age of 
the study population should have produced a decline in the number of HR-HPV positive women. 
The same protocol for HPV testing was used in both surveys and therefore the increase in HPV 
prevalence could not be attributed to an increase in sensitivity of HPV testing, but rather to an 
increase in exposure to HPV. A possible explanation for this is a change in sexual behavior; 
national health surveys have shown an increasing lifetime number of sexual partners among 
Chilean women [5]. In our cohort, women who acquired new HR-HPV infections had a greater 
increase in high-risk sexual behaviors than those who did not, though this difference did not reach 
statistical significance. The observed increase in HR-HPV infections suggests that a close 
surveillance of these infections and their associated lesions should be considered. 
 
The age distribution of new infections showed a first peak in the youngest and a second peak at 
age 45 to 55 years old at follow-up. This second peak has been previously described in other Latin 
American countries [6]; however its significance is unclear, as it could represent newly acquired 
infections or dormant infections that have resurfaced in relation to menopausal changes. Based on 
the first hypothesis, some have recommended vaccination for adult women [7], while the second 
hypothesis suggests a more conservative approach. Answering this question will require more 
mechanistic research. 
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HR-HPV type-specific persistence increased with age, which is in line with findings reported in 
other studies [8, 9]. Our finding that all HR-HPV infection cleared in women under age 30 
indicates that the current recommendation of HPV screening for women over 30 years of age 
applies in our population [10, 11]. 
 
Women with type-specific HR-HPV persistence are at high risk of developing cervical cancer [12-
15] and should be under tight surveillance for precancerous lesions; they represent 3.1% (18 out of 
576) of our study population. Our results indicate that if a screening program were implemented 
using a test like Hybrid Capture 2, which does not identify specific types of HR-HPV, 4.7% of our 
population would be called for further work up, thus including the 1.6% of women who in fact did 
not persist with the same HR-HPV type. This possibly unnecessary follow-up could be avoided if 
a type-specific test were used, but this should be balanced against the higher cost of the test.  
Recent studies conducted in Canada [16], Mexico [17], South Africa [18], Europe and the US [19] 
have shown that implementation of an HPV screening strategy, even without genotyping, can be 
highly cost effective when compared with cytology screening alone.  
 
A major strength of this study is that it is the first in Chile that follows a population-based cohort 
of women to learn about the natural history of HR-HPV infection in our population. Other 
strengths include the broad age range of enrolled women, the collection of comprehensive 
information on risk factors, and the performance of DNA testing at a world reference laboratory. 
 
In conclusion, HR-HPV prevalence in our study population increased during the follow-up period, 
presumably the result of changes in sexual behavior, which could lead to an increase in cervical 
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cancer in this population. In order to strengthen our prevention programs, newly available tools 
such as HPV-based screening tests should be considered in Chile. In our study, all HR-HPV 
infections in women under 30 years old cleared, supporting the current recommendation of HR-
HPV screening for women over 30 years of age. 
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HPV, human papillomavirus; HR, high-risk; ASCUS, atypical squamous cells of undetermined 
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TABLES 
 
Table 1 – Baseline characteristics associated with participation in follow-up study and with 
high-risk HPV infection outcome.  
Participation in follow-up study HR-HPV infection outcome                           (Univariate) Category 
Enrolled 
2001 
Followed 
2006 Multivariate Type-specific Persistence Incidence                       
Characteristic 
at enrollment 
in 2001 
   (n=969)* (n=576)* P value OR (95% CI)** OR (95% CI)*** 
Age  < 30 years old  23.4 19.8 0.813 Inf 2.11 (1.17-3.80) 
Marital Status  Single/separated/
widowed 24.4 20.7 0.169 0.18 (0.02-1.61) 0.40 (0.17-0.97) 
Schooling  ≤ 8 years 58.5 61.6 0.011 5.00 (1.21-20.69) 1.24 (0.70-2.19) 
Nº of Children  ≥3  55.8 59.3 0.077 1.44 (0.43-4.85) 0.74 (0.43-1.28) 
Age First Sexual 
Intercourse ≤16 years old  36.0 35.8 0.681 0.68 (0.21-2.17) 1.36 (0.79-2.36) 
Lifetime Sexual 
Partners >1  39.6 36.0 0.701 0.74 (0.23-2.34) 0.78 (0.43-1.41) 
Current High-risk 
Sexual Partner a  Yes  31.0 29.8 0.311 1.93 (0.49-7.61) 0.60 (0.27-1.35) 
Condom Use  Never  84.0 85.5 0.045 0.18 (0.02-2.16) 0.90 (0.41-2.01) 
History of STD b  Yes  3.8 4.2 0.222 1.88 (0.11-32.01) 0.36 (0.05-2.75) 
Current 
Hormonal 
Contraception 
Yes  12.0 13.3 0.733 0.39 (0.10-1.54) 1.33 (0.75-2.38) 
Current Smoker  Yes  40.5 38.5 0.427 0.47 (0.14-1.55) 0.74 (0.42-1.31) 
Previous Pap 
Test No  21.2 17.0 0.7 14.35 (0.78-262.64) 1.97 (1.06-3.67) 
Abnormal 
Baseline Pap c  Yes 3.8 3.7 0.904 0.32 (0.06-1.68) 0.92 (0.21-4.05) 
Baseline HPV 
Status  
HR-HPV 
positive 9.6 8.9 0.999  -- 3.56 (1.77-7.16) 
* values presented as percentages. 
** referent: women who in 2006 had cleared a HR-HPV genotype present in 2001. 
*** referent: women who did not acquire a new HR-HPV genotype in 2006. 
a
 partner had sex with other women during their relationship or ever had sex with prostitute. 
b
 sexually transmitted disease. 
c
 ASCUS or worse. 
Bold: statistically significant at P value <0.05. 
Inf: infinite odds ratio since the characteristic was present in 0% of cases; thus the CI is 
incalculable. 
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Table 2 – High-risk HPV infections in a cohort of 576 women – Santiago, Chile 
2001 2006 Prevalence Rate Ratio 
HR-HPV type women  % women  % 2006/2001 95% CI 
Any HR-HPV 51 8.8 73 12.7 1.4 1.02 - 2.01 
HPV 16  12 2.1 19 3.3 1.6 0.78 - 3.23 
HPV 18  3 0.5 16 2.8 5.3 1.56 - 18.20 
HPV 31  8 1.4 5 0.9 0.6 0.21 - 1.90 
HPV 33  2 0.4 1 0.2 0.5 0.05 - 5.50 
HPV 35  2 0.4 3 0.5 1.5 0.25 - 8.94 
HPV 39  4 0.7 8 1.4 2.0 0.61 - 6.61 
HPV 45  3 0.5 10 1.7 3.3 0.92 - 12.05 
HPV 51  1 0.2 5 0.9 5.0 0.59 - 42.67 
HPV 52  2 0.4 6 1.0 3.0 0.61 - 14.80 
HPV 56  8 1.4 11 1.9 1.4 0.56 - 3.39 
HPV 58  7 1.2 4 0.7 0.6 0.17 - 1.94 
HPV 59  4 0.7 2 0.4 0.5 0.09 - 2.72 
HPV 66  2 0.4 2 0.4 1.0 0.14 - 7.08 
HPV 68 
  
1 0.2 0 0.0 0.0 -- 
Bold: statistically significant. 
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Table 3 – High-risk HPV status after 5 years in a cohort of 576 women - Santiago, Chile 
Prevalence Incidence Persistence 
any type type-specific Age 
in 2001 
years 
Number 
of 
women 
2001 
n (%) 
2006 
n (%) n (%) n (%) 
% of 
cohort n (%) 
% of 
cohort 
≤ 20 36 5 (13.9) 7 (19.4) 7 (19.4) 0 (0.0) 0.0 0 (0.0) 0.0 
21 - 30 84 8 (9.5) 12 (14.3) 12 (14.3) 2 (25.0) 2.4 0 (0.0) 0.0 
31 - 40 112 9 (8.0) 9 (8.0)* 7 (6.2) 4 (44.4) 3.6 3 (33.3) 2.7 
41 - 50 157 9 (5.7) 21 (13.4) 17 (10.8) 6 (66.7) 3.8 4 (44.4) 2.5 
51 - 60 111 12 (10.8) 14 (12.6)* 11 (9.9) 7 (58.3) 6.3 5 (41.7) 4.5 
61 - 70 58 5 (8.6) 7 (12.1)* 5 (8.6) 5 (100) 8.6 3 (60.0) 5.2 
> 70 18 3 (16.7) 3 (16.7) 0 (0.0) 3 (100) 16.7 3 (100) 16.7 
All 576 51 (8.9) 73 (12.7)* 59 (10.2) 27 (52.9) 4.7 18 (35.3) 3.1 
Prevalence: women testing positive for one or more high-risk HPV genotypes in a given year. 
Incidence: women with one or more newly detected high-risk HPV genotypes in 2006. 
Persistence, any type: women testing positive for one or more high-risk HPV genotypes in both 
2001 and 2006, regardless of genotype. 
Persistence, type-specific: women testing positive for the same high-risk HPV genotype(s) in both 
2001 and 2006. 
* The number of incident cases plus the number of type-specific persistent cases does not equal 
the number of prevalent cases because some women have both a persistent high-risk HPV 
genotype and a newly detected one. 
